BioArctic signed the first deal for its “brain transporter” with Bristol Myers Squibb late last year. The deal is worth up to $1.4bn and allows the US drugmaker to start trials using the technology to ...

Revolutionary antibody discovery platform targets protein aggregation in Alzheimer`s and Parkinson`s, offering new ...

FAIR Health recently introduced a new — and free — shared Alzheimer's decision-making tool, providing older adults and their families with essential guidance on treatment options and costs. Developed ...

More than a decade after hosting clinical trials for two medications now commonly used to slow the progression of Alzheimer’s ...

Cognitive decline can range from mild memory issues to severe dementia, with Alzheimer’s disease being the most common form.

Professor Seán Kennelly from the Tallaght Institute of Memory and Cognition believes this study is a major step forward in ...

US researchers behind the new analysis said they hoped the findings would help patients weigh up the potential benefits of ...

In diseases like Parkinson's and Alzheimer's, specific proteins misfold and clump together, forming toxic aggregates that ...

Alzheimer's disease, a type of dementia that profoundly alters a person’s memory and cognitive function, affects an estimated ...

Progressive and incurable, Alzheimer’s disease affects an estimated 6.7 million U.S. adults at least 65 years old, according ...

Scientists have identified a biomarker for Alzheimer's that may help doctors spot the early signs of protein buildup in the ...

Fraud, Arrogance, and Tragedy in the Quest to Cure Alzheimer’s,” Charles Piller looks how the amyloid hypothesis took over ...